Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Matti AaproFlorian ScotteYolanda EscobarLuigi CelioRichard BermanAlessandra FranceschettiDanielle BellKarin JordanPublished in: The oncologist (2021)
Despite recent advances in antiemetic therapy, a substantial proportion of patients experience nausea and vomiting associated with chemotherapy in daily clinical practice. Antiemetic guidelines aim at prevention of chemotherapy-induced nausea and vomiting (CINV), and guideline-consistent antiemetic therapy can effectively prevent vomiting and, to a lesser extent, nausea in most patients with cancer. This study reports low adherence to antiemetic guidelines in the highly emetogenic chemotherapy setting in daily clinical practice across five European countries. Opportunity exists to increase adherence to antiemetic guideline recommendations. Implementation of strategies to facilitate guideline adherence can potentially improve CINV control.
Keyphrases
- chemotherapy induced
- clinical practice
- primary care
- end stage renal disease
- glycemic control
- ejection fraction
- healthcare
- physical activity
- newly diagnosed
- stem cells
- type diabetes
- prognostic factors
- squamous cell carcinoma
- chronic kidney disease
- adverse drug
- quality improvement
- adipose tissue
- machine learning
- skeletal muscle
- metabolic syndrome
- deep learning
- peritoneal dialysis
- big data
- artificial intelligence
- patient reported
- rectal cancer